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Abstract
Background—Previous small studies found that BRCA1 and BRCA2 breast tumors differ in
their pathology. Analysis of larger datasets of mutation carriers should allow further tumor
characterization.
Methods—We used data from 4,325 BRCA1 and 2,568 BRCA2 mutation carriers to analyze the
pathology of invasive breast, ovarian and contralateral breast cancers.
Results—There was strong evidence that the proportion of estrogen receptor (ER)-negative
breast tumors decreased with age at diagnosis among BRCA1 (p-trend=1.2×10−5) but increased
with age at diagnosis among BRCA2 carriers (p-trend=6.8×10−6). The proportion of triple
negative tumors decreased with age at diagnosis in BRCA1 carriers but increased with age at
diagnosis of BRCA2 carriers. In both BRCA1 and BRCA2 carriers, ER-negative tumors were of
higher histological grade than ER-positive tumors (Grade 3 vs. Grade 1, p=1.2×10−13 for BRCA1
and p=0.001 for BRCA2). ER and progesterone receptor (PR) expression were independently
associated with mutation carrier status (ER-positive odds ratio (OR) for BRCA2=9.4, 95%CI:
7.0-12.6 and PR-positive OR=1.7, 95%CI:1.3-2.3, under joint analysis). Lobular tumors were
more likely to be BRCA2-related (OR for BRCA2=3.3, 95%CI:2.4-4.4, p=4.4×10−14), and
medullary tumors BRCA1-related (OR for BRCA2=0.25, 95%CI:0.18-0.35, p=2.3×10−15). ER-
status of the first breast cancer was predictive of ER-status of asynchronous contralateral breast
cancer (p=0.0004 for BRCA1; p=0.002 for BRCA2). There were no significant differences in
ovarian cancer morphology between BRCA1 and BRCA2 carriers (serous:67%; mucinous:1%;
endometriod:12%; clear-cell:2%).
Conclusions/Impact—Pathology characteristics of BRCA1 and BRCA2 tumors may be useful
for improving risk prediction algorithms and informing clinical strategies for screening and
prophylaxis.
Keywords
pathology; breast; BRCA1; BRCA2; contralateral
Introduction
The tumor suppressor genes BRCA1 and BRCA2 are associated with high risks of breast,
ovarian and contralateral breast cancer. Tumors arising in BRCA1 and BRCA2 mutation
carriers display characteristic pathological features (1-3). Cancers occurring among BRCA1
carriers are more frequently classified as medullary (1, 4, 5) and exhibit higher grade and
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mitotic count than sporadic controls (2, 6-8). Numerous studies have linked the estrogen
receptor (ER)-negativity of breast tumors with BRCA1 mutation carrier status (6, 9-16).
Tumors arising in BRCA1 carriers also tend to lack progesterone receptors (PR) and HER2,
and hence display the “triple negative” (TN) phenotype (6, 10). The majority of BRCA1
tumors express basal cytokeratins (17) and fall into the ‘basal’ subtype in gene expression
studies (18).
Breast cancers arising in BRCA2 mutation carriers tend to be more heterogeneous than those
arising in BRCA1 mutation carriers (19). They exhibit higher grade than tumors from age-
matched sporadic controls (6, 7, 20). Several investigators have reported similar prevalence
of ER-positive tumors in BRCA2 carriers compared with sporadic controls (6, 9, 16, 17),
although in one study (20) BRCA2 tumors were more often ER-positive. BRCA2 tumors are
less likely to be HER2 overexpressing/amplified compared with sporadic tumors (6, 17).
However, most studies of BRCA2 mutation carriers have been small and detailed tumor
pathology information from BRCA2 carriers has been sparse.
Similarly, pathology studies conducted on contralateral breast cancer (21) and ovarian
cancer (22-24) arising in BRCA1 and BRCA2 mutation carriers have been small in size.
Here we report pathology data from the Consortium of Investigators of Modifiers of
BRCA1/2 (CIMBA), which is the largest collaborative study of BRCA1 and BRCA2
mutation carriers of its kind. We assessed the morphology, grade and pathological markers
in breast tumors arising in BRCA1 or BRCA2 carriers, and estimated age-specific
distributions of the different disease subtypes. Where possible, these distributions were
compared with published data for the general population. We also compared the pathology
of tumors arising in BRCA1 and BRCA2 mutation carriers in order to identify
characteristics that could distinguish between BRCA1 and BRCA2 mutation carriers. Such
information is relevant for developing algorithms that predict mutation carrier status or
breast cancer risk. For ovarian cancer, we assessed grade and morphological features of
tumors. For contralateral breast cancer, we examined the relationship between pathology of
the second and first invasive breast cancer. The size of the present dataset allowed the study
of smaller subsets of disease, such as ER-positive tumors in BRCA1 mutation carriers or TN
tumors in BRCA2 mutation carriers and the estimation of age-specific proportions of tumor
subtypes in BRCA1 and BRCA2 mutation carriers, which are currently imprecise. One of
the aims of this work was to replicate findings based on single reports or much smaller
studies. The results of these analyses should be useful for improving breast cancer risk
prediction algorithms and may inform screening practices for, and prophylaxis of, cancers
arising in BRCA1 and BRCA2 mutation carriers.
Materials and Methods
Study participants
Eligibility to CIMBA is restricted to female BRCA1 or BRCA2 pathogenic mutation
carriers who are 18 years or older (25). Thirty-seven groups from North America, Australia
and Europe submitted data for this analysis (Supplementary Table 1). Information collected
included year of birth, age at diagnosis of breast and/or ovarian cancer, age at last
observation, family membership, race/ethnicity and information on bilateral prophylactic
mastectomy and oophorectomy. All centers obtained informed consent from study
participants and local ethical review committees approved protocols.
The present analysis was restricted to mutation carriers who had been diagnosed with breast
or ovarian cancer for whom information on tumor pathological characteristics was available,
and to women of self-reported white European ancestry. The number of mutation carriers of
non-European ancestry with data on tumor pathology was too small to allow a meaningful
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analysis. Information on at least one tumor characteristic was available for 4,325 BRCA1
and 2,568 BRCA2 mutation carriers.
Tumor pathology data
Pathology data were derived from medical, pathology or tumor registry records or confirmed
by pathological review. For some cases, tumor pathology was based on
immunohistochemical staining and scoring of tissue microarrays (TMAs). The source of the
data collected by each center is shown in Supplementary Table 1. For approximately 1,000
cases detailed information on breast cancer pathology, for example staining intensity or
proportion of cells staining, accompanied the summary result in the pathology records. This
information was cross-checked against the marker status provided. In case of any
discrepancies, the most widely used definitions for the receptor status shown in
Supplementary Table 2 were used. Grades 1, 2 and 3 represent well-differentiated,
moderately differentiated, and poorly/undifferentiated tumors, respectively. However, no
information was available on the tumor grading system used at each center. Data were
analyzed by individual hormone receptor status, joint expression of ER and PR, and HER2.
Mutation class and position
Mutations in the BRCA1 and BRCA2 genes can be classified according to their potential
functional effect (26-28). Class 1 mutations are loss-of-function mutations, expected to
result in a reduced transcript or protein level due to mRNA nonsense-mediated decay and/or
degradation or instability of truncated proteins, translation reinitiation but no production of
stable protein, or the absence of expression because of the deletion of transcription
regulatory regions. Class 2 mutations are those likely to generate potentially stable mutant
proteins that might have dominant negative action, partially preserved normal function, or
loss of function. Class 2 mutations include missense substitutions, in-frame deletions and
insertions, as well as truncating mutations with premature stop codons occurring in the last
exon. Mutations whose consequences at the transcript or protein level could not be inferred
were not considered for this classification.
Mutations occurring in the central portion of the BRCA2 gene (NG_012772), previously
referred to as the “ovarian cancer cluster region” (OCCR), are associated with a higher ratio
of ovarian: breast cancer versus mutations outside this region (29, 30). We used the
definition of the OCCR determined by Thompson et al. (30), as bounded by nucleotides
corresponding to regions c.2831-c.3847, and c.6275-c.6401 according to the HGVS
nomenclature. As there is uncertainty in defining precise boundaries, the wider region c.
2831-c.6401 was used.
Statistical methods
Logistic regression was used to assess the association between pathological characteristics
and BRCA mutation carrier status. For assessment of continuous or ordered variables such
as grade and age, tests for trend were also performed. When comparing the pathological
characteristics of BRCA1 and BRCA2 mutation carriers, cases from countries where the
mutation carriers had a mutation exclusively in either BRCA1 or BRCA2 (e.g., Iceland)
were excluded. All analyses were adjusted for age at diagnosis and for country of origin. A
robust variance approach was used to allow for dependencies between related individuals.
All analyses were performed in Stata v10.
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Results
Pathological characteristics of breast tumors arising in BRCA1 and BRCA2 mutation
carriers
The analysis was based on 3,797 BRCA1 mutation carriers and 2,392 BRCA2 mutation
carriers diagnosed with invasive breast cancer. Median age at diagnosis of invasive breast
cancers was 40 years (interquartile range (IQR): 12.3) among BRCA1 and 43 years (IQR:
13) among BRCA2 mutation carriers. The majority of invasive breast cancers arising in both
BRCA1 and BRCA2 carriers were ductal/no special-type carcinomas (Table 1). 78% of
tumors arising in BRCA1 carriers were ER-negative, 79% were PR-negative, 90% HER2-
negative and 68% TN. 23% of tumors arising in BRCA2 mutation carriers were ER-
negative, 35% were PR-negative, 87% were HER2-negative, and 16% were triple negative.
Age-specific proportions of invasive breast tumors arising in BRCA1 and BRCA2 mutation
carriers which were of histological Grade 1, Grade 2, or Grade 3 are shown in Figure 1. The
number of women included in these analyses is shown in Supplementary Table 3. Age at
diagnosis was associated with grade in BRCA1 mutation carriers, in whom grade decreased
with increasing age (ordered logistic regression, p-trend=1.4×10−15). There was no evidence
of a similar trend among BRCA2 mutation carriers (ordered logistic regression, p-
trend=0.07), however, the ratio of Grade 1 to Grade 3 tumors increased with increasing age
(p=6×10−5).
Age-specific proportions of ER-negative, PR-negative, HER2-negative and TN invasive
breast tumors arising in BRCA1 and BRCA2 mutation carriers are shown in Figure 2. The
frequency of ER-negative tumors decreased with the age at breast cancer diagnosis in
BRCA1 mutation carriers (p-trend=1.2×10−5), and increased with the age at diagnosis in
BRCA2 mutation carriers (p-trend=6.8×10−6). The distribution of PR status showed similar
trends, decreasing with age at diagnosis in BRCA1 (p-trend = 0.02) and increasing with age
at diagnosis in BRCA2 (p-trend=6.1×10−5) carriers. There was no evidence of variation in
the distribution of HER2 status by age at diagnosis (p-trend=0.8 and p=0.9 for BRCA1 and
BRCA2 mutation carriers, respectively). However, the number of tumors with HER2
information was limited at the extreme age groups. The proportion of TN tumors decreased
with age at breast cancer diagnosis in BRCA1 mutation carriers (p-trend=0.01), and
increased with age at diagnosis in BRCA2 carriers (p-trend=0.001).
The analyses above were adjusted for grade; analyses without this adjustment yielded
similar results. The associations were also not confounded by calendar time of diagnosis.
For example, after adjusting for 5-year cohorts based on calendar year of diagnosis, the
associations between ER status and age at diagnosis was still significant for both BRCA1
and BRCA2 mutation carriers (p-trend=2×10−5 and p-trend=1.2×10−5 respectively).
For both BRCA1 and BRCA2 mutation carriers there were significant differences in the
distribution of tumor grade by ER status (Table 2, Figure 3) ER-negative tumors were
associated with higher grade than ER-positive tumors. For example, in BRCA1 mutation
carriers, grade 3 tumors were less likely to be ER-positive than grade 1 tumors (odds ratio
(OR) for ER-positivity 0.12, 95%CI:0.07-.21, p=1.2×10−13). For BRCA2 mutation carriers,
grade 3 tumors were less likely to be ER-positive compared with grade 1 tumors (OR for
ER-positivity, 0.33, 95%CI:0.17-0.63, p=0.001). The distribution of tumor morphology by
ER status is also shown in Table 2.
We tested the hypothesis that mutation class or intragenic position influences tumor
characteristics. About 66% of BRCA1 mutation carriers harbored Class 1 mutations and
25% Class 2 mutations. Class 2 mutations were infrequent among BRCA2 mutation carriers.
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There were no significant differences between class of BRCA1 mutation and tumor
pathology of BRCA1-related tumors. There were also no differences in characteristics of
BRCA2-related tumors according to whether the mutation was within the OCCR region
(32% of mutation carriers) or outside the OCCR (68% of mutation carriers) (results not
shown).
Information was also available on a small number of pre-invasive, ductal carcinomas in situ
(DCIS). Compared with invasive breast tumors, a higher proportion of DCIS arising in
BRCA1 and BRCA2 mutation carriers were ER-positive (Supplementary Table 4).
Comparison of BRCA1 and BRCA2 tumors
We compared the morphological characteristics of tumors arising in BRCA1 and BRCA2
mutation carriers. There were significantly more lobular carcinomas among BRCA2 carriers
than among BRCA1 carriers (p=4.4×10−14), and significantly more medullary or atypical
medullary carcinomas among BRCA1 mutation carriers than among BRCA2 carriers
(p=2.3×10−15, Table 1).
Logistic regression analysis, treating receptor status (positive/negative) as the explanatory
variable and BRCA1/BRCA2 mutation status as the outcome variable, was used to test
association between tumor characteristics and BRCA mutation carrier status. ER-positive
tumors were more likely to arise in BRCA2 than BRCA1 (Table 1, OR for BRCA2=11.4,
95% CI: 9.8-13.2) and this was true in all morphology categories (OR for BRCA2=10.2,
95%CI: 8.2-12.6 among ductal/no special-type carcinoma tumors; OR=26.6, 95%CI:
4.4-159 among lobular carcinoma tumors; and OR=5.6, 95%CI: 1.8-17.2 among medullary
carcinoma tumors). PR-positive (OR=6.8, 95% CI: 5.8-7.9), HER2-positive (OR=1.5, 95%
CI: 1.1-2.1) and non-TN tumors (OR=11.0, 95% CI: 8.8-13.8) were also more likely to be
BRCA2 than BRCA1 (Table 1). The associations remained significant after adjusting for
tumor grade except HER2. Tumors arising in BRCA1 mutation carriers were of significantly
higher histological grade than those arising in BRCA2 mutation carriers (Table 1). However,
this difference was not significant when the analysis was adjusted for ER status.
Although ER and PR are highly correlated, expression of these hormone receptors is
discordant in a small proportion of tumors. The tumors were therefore analyzed by joint ER
and PR status (Supplementary Table 5). PR-positivity was associated with BRCA2 mutation
carrier status in ER-negative tumors. PR-positivity was also associated with BRCA2
mutation carrier status in the ER-positive subset of tumors (OR for BRCA2=1.5, 95%CI:
1.1-2.0, p=0.01). There was no statistically significant difference in the distribution of HER2
among BRCA1 and BRCA2 mutation carriers when ER and/or PR positive tumors were
analyzed separately, but TN tumors were significantly associated with BRCA1 carrier status
compared with HER2-positive ER-negative PR-negative tumors (Supplementary Table 5).
In a model incorporating the joint effects of ER, PR and HER2 in predicting BRCA2 vs.
BRCA1 mutation carrier status, both ER and PR remained significant, but HER2 status was
not (ER: OR=9.4, 95%CI:7.0-12.6; PR: OR=1.7, 95%CI:1.3-2.3; HER2, OR=1.1, 95%CI:
0.7-1.6).
Pathological characteristics of first and contralateral breast tumors
Pathology information was available for 720 BRCA1 and 302 BRCA2 mutation carriers
diagnosed with invasive contralateral breast cancer (CBC). The median time interval
between first breast cancer and CBCs was 5.2 years (inter-quartile range (IQR): 7.5) for
BRCA1 and 5.0 years (IQR: 9.3) for BRCA2 carriers. The median age at diagnosis of
asynchronous CBC occurring more than 1 year after diagnosis of the first breast cancer, was
46 years (IQR: 13.6) for BRCA1 and 51 years (IQR: 13.9) for BRCA2 mutation carriers.
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Morphology, grade, ER and PR status of the first invasive and asynchronous cancers are
summarized in Supplementary Tables 6-9. For BRCA1 mutation carriers, 91% of women
with ER-negative first breast cancer developed ER-negative asynchronous CBC occurring
more than a year after the first cancer, while 70% of women with ER-positive first cancer
developed ER-negative asynchronous CBC. For BRCA2 mutation carriers, 52% of women
with ER-negative first cancer developed ER-negative asynchronous CBC and 12% of
women with ER-positive first cancer developed ER-negative asynchronous CBC. Logistic
regression analysis, treating receptor status (positive/negative) of the second cancer as the
outcome variable and receptor status of the first cancer as the explanatory variable indicated
that the ER status of the first breast cancer was predictive of ER status of the CBC for
BRCA1 mutation carriers (OR =5.8, 95%CI:2.8-11.7, p=1.2×10−6, Supplementary Table 8)
as well as for BRCA2 mutation carriers (OR=11.0, 95%CI:4.3-28.6, p=7.8×10−7). The
conclusions were similar when the analyses were restricted to asynchronous contralateral
cancers (OR=4.3, 95%CI:1.9-9.7, p=0.0004 for BRCA1, and OR=6.4, 95%CI:2.0-20.9,
p=0.002 for BRCA2 carriers, Supplementary Table 8). There were smaller numbers of
carriers with information on both ER status and grade. When adjusted for grade the
association remained significant in BRCA1, but was attenuated in BRCA2 carriers, but the
OR estimate was in the same direction (Supplementary Table 8). PR status of the first breast
cancer was also associated with PR status of the second cancer (data not shown).
Pathology characteristics of ovarian cancers
This dataset included 838 BRCA1 mutation carriers and 281 BRCA2 mutation carriers who
had been diagnosed with ovarian cancer. The distribution of pathological characteristics of
the ovarian cancers, are shown in Table 3. The majority (67%) of all cancers (BRCA1 and
BRCA2) were serous. Over 70% of ovarian cancers in BRCA1 mutation carriers were grade
3. There was no association between grade and age at cancer diagnosis (p=0.4). In BRCA2
carriers, the proportion of grade 3 tumors increased slightly with age, whereas the proportion
of grade 1 tumors decreased (ordered logistic regression, p-trend=0.03). 310 BRCA1 and
105 BRCA2 mutation carriers had developed breast cancer prior to ovarian cancer. History
of breast cancer did not influence morphology or grade of ovarian cancer (data not shown).
There were no significant differences in ovarian cancer morphology or grade between
BRCA1 and BRCA2 mutation carriers (p>0.05, for all tests).
Discussion
We analyzed data on the pathology of breast and ovarian tumors arising in a large series of
women with BRCA1 and BRCA2 mutations from the CIMBA consortium. Previous studies
that have assessed tumor pathology in mutation carriers have been limited by small
numbers, particularly among BRCA2 carriers. The present analysis of over 4,000 BRCA1
and 2,000 BRCA2 carriers is the largest of its kind and allowed for accurate assessment of
tumor pathology in mutation carriers, and more powerful comparisons between BRCA1 and
BRCA2-related tumors.
We confirmed that the majority of BRCA1 breast cancers are ER-negative and TN tumors.
We calculated age-specific proportions of tumors expressing pathological markers including
ER, PR, and HER2. The proportion of ER-positive and PR-positive tumors increased with
age among BRCA1 mutation carriers, and decreased with age among BRCA2 mutation
carriers. Analyses adjusting for grade or for calendar year of diagnosis to allow for changes
in screening patterns over time yielded similar results.
Tung et al (8) and Foulkes et al (12) also reported higher prevalence of ER positive tumors
among BRCA1 carriers diagnosed with breast cancer at an older age. Foulkes et al. found
that at every age group the proportion of ER-negative tumours was higher in BRCA1
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mutation carriers than non-carriers (12). We made similar observations comparing with the
publicly available SEER data (31). We further confirmed differences in the distribution of
grade between ER-positive and ER-negative BRCA1 tumors previously seen in smaller
studies (8, 12). Tung et al. also reported differences in pathology between sporadic ER-
positive tumors and ER-positive tumors arising in BRCA1 carriers (8). More recently, they
reported that a similar percentage (80%) of ER-positive and ER-negative BRCA1-associated
tumors showed loss of heterozygosity with loss of the wild-type BRCA1 allele (32). They
suggested that ER-positive tumors in BRCA1 carriers could be a heterogeneous group, in
some cases developing from complete loss of BRCA1 function, while in others with intact
BRCA1 (8). Lakhani et al. further suggested that environmental exposures together with
predisposition of the cells to genomic instability could result in the same cell populations
producing different tumor subtypes (33). However the cell (or cells) of origin of BRCA1-
related tumors have not been determined. These data suggest that ER-positive cancers in
BRCA1-carriers are related to mutation carrier status rather than being incidental. A more
definitive resolution of this question could be obtained by comparing the incidence of ER-
positive tumors in BRCA1 mutation carriers with the incidence of ER-positive tumors in the
general population. This is not yet possible reliably, but in future prospective studies of
cancer incidence should be possible to stratify analyses by tumor subtype.
Several investigators have reported similar prevalence of ER and PR positive disease in
BRCA2 carriers compared with sporadic controls (6, 9, 16, 17). Bane et al. reported higher
prevalence of ER-positive tumors in a series of 64 BRCA2 mutation carriers compared with
age-matched non-carrier controls (20). We found a statistically significant decrease in the
proportion of ER-positive tumors with age at diagnosis of breast cancer in BRCA2 mutation
carriers, consistent with observations in a few much smaller studies (12, 34). Compared to
the publicly available SEER data from the USA, the proportion of ER-negative tumors in
BRCA2 mutation carriers appeared to be somewhat higher than that in women of the same
age-group in the general population (31). Although we could not directly compare the
distribution of pathological markers in mutation carriers and non-carriers in this dataset, this
observation contrasts with the well-established increase in the relative incidence of ER-
positive as compared with ER-negative breast cancers at older ages observed in the general
population (35).
A number of risk prediction models have recently been extended to include tumor pathology
information (36-38). In most of these models, variation in the expression of pathological
markers with age at breast cancer diagnosis was not taken into account. Our results suggest
that using age-specific pathological data in risk prediction models may provide more
accurate mutation carrier predictions. Furthermore, precise characterization of the
distribution of tumor pathology in mutation carriers may influence prophylactic and
treatment strategies. For example, although it is known that TN status is associated with
BRCA1 mutations, in our study 16% (and up to 25% in women aged 50-60 years) of tumors
in BRCA2 mutation carriers were triple negative. Consistent with the above observations on
ER status, we also found that the proportion of TN tumors in BRCA2 carriers increased with
age at diagnosis of breast cancer. This confirms the observation of Atchley et al. (10) in a
smaller series, and contradicts the assumption that a diagnosis of TN disease is
‘synonymous’ with BRCA1 carrier status. TN tumors would be expected to have poorer
prognosis than ER-positive tumors and require chemotherapy. In addition, knowing the
likelihood of developing a TN tumor in a BRCA1 or BRCA2 mutation carrier may influence
the decision to undergo prophylactic surgery.
We confirmed that there are significant differences in the distribution of ER status between
BRCA1 and BRCA2 breast cancers, and also found that PR is independently associated with
mutation carrier status. Our results also suggest that ER-positive, PR-negative tumors were
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less likely to be BRCA2-related than double positive tumors, and ER-negative PR-positive
tumors were more likely to be BRCA2-related than double negative tumors. The ER-
negative and PR-positive subset of tumors, previously considered a technical artefact, has
now been shown in the general population to exhibit unique clinical characteristics,
indicating that it is a distinct biological entity (39). We found no significant association
between HER2 status and BRCA1 or BRCA2 mutation carrier status. However the number
of HER2 overexpressing tumors may have been too small to address this reliably. TN
tumors are more likely to be BRCA1 rather than BRCA2. We also confirmed data showing
that high grade cancers are more frequent among BRCA1 carriers and that these women
have a higher percentage of medullary cancers. By contrast, lobular cancers are substantially
more frequent among BRCA2 carriers.
We found no difference in the distribution of tumor characteristics of BRCA1 mutation
carriers by mutation category, defined by their functional effects. This analysis may be
confounded by the fact that tumor characteristics may be used (together with other factors)
to infer pathogenicity of a small subset of missense Class 2 BRCA1 mutations. In this
dataset only 2% of all BRCA1 mutations would have been in this category. We also found
no difference in the distribution of tumor characteristics of BRCA2 carriers by mutation
position (OCCR vs. non-OCCR). Establishing tumor pathology associated with mutations in
BRCA1 and BRCA2 will further aid in the evaluation of unclassified variants.
We further assessed the pathology of invasive contralateral breast cancers (CBC) occurring
in mutation carriers. Weitzel et al reported strong concordance in ER status between first
and CBC in a study of 211 BRCA1 and 75 BRCA2 carriers (21). These investigators did not
detect a relationship between history of Tamoxifen use or risk-reducing salphingo-
oophorectomy and ER status of CBC in BRCA1/2 mutation carriers (21). However, Swain
et al found that patients in the general population with an ER-positive primary cancer
receiving Tamoxifen exhibited lower concordance rate with fewer ER-positive contralateral
breast cancers (40). In our study we confirmed the association between ER and PR status of
first invasive breast tumors and contralateral breast cancer, suggesting that second breast
cancers arising against the same genetic and environmental background are of similar
pathology. However the majority (70%) of BRCA1 mutation carriers diagnosed with ER-
positive first breast cancers developed ER-negative CBC. Future CIMBA studies will aim to
compare the tumor pathology of cancers occurring after RRSO.
In agreement with other reports, most ovarian cancers arising in BRCA1 and BRCA2
mutation carriers in our series were invasive epithelial cancers of serous histology, and we
found no significant difference in morphology and grade of BRCA1 and BRCA2-related
tumors (22-24).
CIMBA, an international collaboration, was represented by more than 37 groups from more
than 20 countries in the present study. Tumor pathology data were collected through several
mechanisms, including medical records, pathology reports and TMAs. Laboratory methods
for tissue preparation, immunohistochemistry and biochemical assays, scoring systems and
data interpretation vary widely (Supplementary Table 1). However, data collated by CIMBA
are more representative of typical assessment of pathology conducted in routine practice,
and the distributions of ER and PR status across different study centers and countries in
CIMBA were generally consistent. There was some variation in the distribution of HER2
status across centers. This could perhaps be explained by technical issues relating to testing
of HER2 and differences in the definition of HER2 status between centers. There was also
some variation in the distribution of grade and morphology across countries. Unfortunately,
details of scoring for all mutation carriers were not available to standardize definitions
across centers. Furthermore, data on the methods of detection of each tumor or treatment
Mavaddat et al. Page 11
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2012 July 01.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
prior to pathological analysis were not available, and these factors may influence the
distribution of tumor subtypes detected (41). Future CIMBA studies will aim to collect
TMA data and fixed tissue samples for rapid analysis of other markers, such as basal
cytokeratins, p53, or novel candidates, and to further standardize collation of information on
established markers.
A further limitation of our study is that CIMBA collects data only BRCA1 and BRCA2
mutation carriers. Therefore, we were unable to contrast the tumor characteristics in
mutation carriers against the characteristics of breast cancers from the general population or
from breast cancer patients without BRCA1 and BRCA2 mutations. Such an analysis would
require careful selection of control subjects from the same populations who are sampled
under similar conditions as BRCA1 and BRCA2 mutation carriers.
The genetic factors underlying aetiology of breast cancer subtypes are still not fully
understood. Previous studies have reported that ER-negative tumors arising in BRCA1 and
BRCA2 mutation carriers, presented higher genomic instability and patterns of genomic
alteration than ER-positive tumors (42, 43). Many of the common breast cancer
susceptibility alleles identified through GWAS are predominantly associated with either ER-
positive or ER-negative disease. The pattern of association with ER-positive and ER-
negative disease parallels those observed in BRCA2 and BRCA1 mutation carriers,
respectively (44), suggesting that common mechanisms underlie the phenotype of tumors in
both mutation carriers and the general population. Recently associations between the
common breast cancer susceptibility alleles and separate disease subtypes in BRCA1 and
BRCA2 mutation carriers were assessed, using data on the tumor subtype distributions
presented here (Mulligan et al., In press). Mulligan et al. (In press) demonstrated differences
in the associations of genetic modifiers with the risk of developing ER-positive or ER-
negative breast cancer in BRCA1 and BRCA2 mutation carriers. These associations mirror
similar differences in genetic susceptibility to ER-positive or ER-negative disease seen in
the general population (45, 46) . The apparent differences in SNP associations between
BRCA1 and BRCA2 carriers, and non-carriers observed previously, may be explained by
differences in the prevalence of tumor subtypes.
The present CIMBA study is the largest of its kind, allowing more accurate characterization
of the pathology of BRCA1 and BRCA2 tumors. As participants were collated from diverse
countries and study centers, the findings should be widely applicable. We were able to
calculate precise age-specific distributions of markers expressed, and replicate findings
reported in only a few small studies to date. This information should be helpful for
improving the performance of breast cancer risk prediction models that calculate BRCA1
and BRCA2 mutation carrier probabilities, or for developing algorithms that predict the risk
of specific breast cancer subtypes for mutation carriers. These may be of clinical utility in
guiding screening and prophylactic practices for mutation carriers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Age specific proportions of Grade 1, 2 and 3 breast tumors arising in BRCA1 and
BRCA2 mutation carriers
Age specific proportions of Grade 1, Grade 2, and Grade 3 tumors among (A) BRCA1 and
(B) BRCA2 mutation carriers.
Error bars represent robust confidence intervals associated with each proportion.
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Figure 2. Age specific proportions of pathological subtypes of breast tumors arising in BRCA1
and BRCA2 mutation carriers
Age specific proportions of (A) Receptor-negative (ER, PR) (B) HER2-negative, and (C)
triple negative tumors arising in BRCA1 mutation carriers, and of (D) Receptor-negative
(ER, PR) (E) HER2-negative, and (F) triple negative tumors arising in BRCA2 mutation
carriers. ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth
factor receptor 2. Error bars represent robust confidence intervals associated with each
proportion.
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Figure 3. Distribution of Grade within ER-positive and ER-negative BRCA1 and BRCA2
mutation carriers
Age specific proportions of Grade 1, Grade 2, and Grade 3 (A) ER-negative, and (C) ER-
positive breast tumors arising in BRCA1 mutation carriers, and (B) ER-negative, and (D)
ER-positive breast tumors arising in BRCA2 mutation carriers.
ER, estrogen receptor
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Table 3
Distribution of morphology and grade of ovarian tumors arising in BRCA1 and BRCA2 mutation carriers
Factor BRCA1
n (%)
BRCA2
n (%)
Total
n (%)
Morphology Serous 534 (66) 191 (70) 725 (67)
Mucinous 11 (1) 4 (1) 15 (1)
Endometrioid 94 (12) 33 (12) 127 (12)
Clear cell 8 (1) 8 (3) 16 (1)
Other 166 (20) 36 (13) 202 (19)
Total 813 272 1,085
Grade 1 17 (3) 11 (6) 28 (4)
2 104 (20) 37 (21) 141 (20)
3 407 (77) 128 (73) 535 (76)
Total 528 176 704
Number of tumors (n) of each morphology type or grade, and as percentage (%) of all BRCA1 or BRCA2-related tumors where this information is
available
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